Pavurutamab (AMG-701) is a bispecific T-cell engager targeting CD3 and B-cell maturation antigens (BCMA), with an extended half-life derived from Pacanalotamab. Its Fc region is engineered for improved pharmacokinetics, offering potential in immune regulation and treatment of multiple myeloma (MM) [1] [2] [3] [4].
CAS Number:
[2250292-39-6]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted
